David Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Yang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Griffen
Department of Genetics, Albert Einstein College of Medicine, New York, USA
2 shared publications - Mariko Isshiki
Department of Genetics, Albert Einstein College of Medicine, New York, USA
2 shared publications - Andrew D. Cameron
RenBio Inc., Long Island City, New York, NY 11101, USA
1 shared publication - Andy T. Thompson
RenBio Inc., Long Island City, New York, NY 11101, USA
1 shared publication - Carleigh Sussman
RenBio Inc., Long Island City, New York, NY 11101, USA
1 shared publication - Debnath Maji
Case Western Reserve University, Cleveland, OH
1 shared publication
Latest Publications
- 22 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71209
Identifying the Genetic Ancestry of the Pediatric Obesity‐Related Asthma Variant (rs6494395) at Rps27l
Background: Obesity‐related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27‐like) in CD4+ (T‐helper) cells from children with OA compared to cells from healthy‐weight asthma that was associated with the C allele at the rs6494395 locus. Consistent with elevated allele frequencies in populations with Latino and African ancestries, we found a higher allele frequency of rs6494395 in Hispanic/Latino and African American children with OA. Aims: We tested the hypothesis that rs6494395 alleles have ancestry‐specific origins. Materials and Methods: We performed global genomic ancestry analysis using the program ADMIXTURE to characterize the proportions of continental genetic ancestry in each individual. Subsequently, we performed local genomic ancestry analysis using the program RFMix, to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi‐ethnic pediatric cohort where the effect of the variant on obese‐related asthma was discovered. Results: Our results indicate that rs6494395 has an African genetic ancestral origin. Conclusions: Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.
- 22 July 2025
- Published by Wiley in Pediatric Pulmonology
- Vol. 60 (7) , e71209
Identifying the Genetic Ancestry of the Pediatric Obesity‐Related Asthma Variant (rs6494395) at Rps27l
Background: Obesity‐related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27‐like) in CD4+ (T‐helper) cells from children with OA compared to cells from healthy‐weight asthma that was associated with the C allele at the rs6494395 locus. Consistent with elevated allele frequencies in populations with Latino and African ancestries, we found a higher allele frequency of rs6494395 in Hispanic/Latino and African American children with OA. Aims: We tested the hypothesis that rs6494395 alleles have ancestry‐specific origins. Materials and Methods: We performed global genomic ancestry analysis using the program ADMIXTURE to characterize the proportions of continental genetic ancestry in each individual. Subsequently, we performed local genomic ancestry analysis using the program RFMix, to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi‐ethnic pediatric cohort where the effect of the variant on obese‐related asthma was discovered. Results: Our results indicate that rs6494395 has an African genetic ancestral origin. Conclusions: Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.
- Open Access
- 17 September 2024
- Published by Wiley
Identifying the Genetic Ancestry of the Pediatric Obesity-related Asthma Variant (rs6494395) at RPS27L
Obesity-related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27-like) in CD4+ (T-helper) cells from children with OA compared to cells from healthy-weight asthma (HwA) that was associated with the C allele at rs6494395 locus. In keeping with elevated allele frequencies in populations with Latino and African ancestries, we found higher allele frequency of rs6494395 in Hispanic and African American children with OA. Therefore, we tested the hypothesis that rs6494395 is ancestry-specific. We performed global and local genomic ancestry analysis using the programs ADMIXTURE and RFMix, respectively, to characterize the genetic ancestry of the cohort and to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi-ethnic pediatric cohort where the effect of the variant on obese-related asthma was discovered. Our results indicate that rs6494395 is of African genetic ancestry. Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.
- 17 September 2024
- Published by Wiley
Open AccessIdentifying the Genetic Ancestry of the Pediatric Obesity-related Asthma Variant (rs6494395) at RPS27L
Obesity-related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27-like) in CD4+ (T-helper) cells from children with OA compared to cells from healthy-weight asthma (HwA) that was associated with the C allele at rs6494395 locus. In keeping with elevated allele frequencies in populations with Latino and African ancestries, we found higher allele frequency of rs6494395 in Hispanic and African American children with OA. Therefore, we tested the hypothesis that rs6494395 is ancestry-specific. We performed global and local genomic ancestry analysis using the programs ADMIXTURE and RFMix, respectively, to characterize the genetic ancestry of the cohort and to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi-ethnic pediatric cohort where the effect of the variant on obese-related asthma was discovered. Our results indicate that rs6494395 is of African genetic ancestry. Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.
- Open Access
- 17 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 547
Enhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies
Electroporation (EP) stands out as a promising non-viral plasmid delivery strategy, although achieving optimal transfection efficiency in vivo remains a challenge. A noteworthy advancement in the field of in vivo EP is the application of hyaluronidase, an enzyme with the capacity to degrade hyaluronic acid in the extracellular matrix, which thereby enhances DNA transfer efficiency by 2- to 3-fold. This paper focuses on elucidating the mechanism of hyaluronidase’s impact on transfection efficiency. We demonstrate that hyaluronidase promotes a more uniform distribution of plasmid DNA (pDNA) within skeletal muscle. Additionally, our study investigates the effect of the timing of hyaluronidase pretreatment on EP efficiency by including time intervals of 0, 5, and 30 min between hyaluronidase treatment and the application of pulses. Serum levels of the pDNA-encoded transgene reveal a minimal influence of the hyaluronidase pretreatment time on the final serum protein levels following delivery in both mice and rabbit models. Leveraging bioimpedance measurements, we capture morphological changes in muscle induced by hyaluronidase treatment, which result in a varied pDNA distribution. Subsequently, these findings are employed to optimize EP electrical parameters following hyaluronidase treatment in animal models. This paper offers novel insights into the potential of hyaluronidase in enhancing the effectiveness of in vivo EP, as well as guides optimized electroporation strategies following hyaluronidase use.
- 17 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 547
Open AccessEnhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies
Electroporation (EP) stands out as a promising non-viral plasmid delivery strategy, although achieving optimal transfection efficiency in vivo remains a challenge. A noteworthy advancement in the field of in vivo EP is the application of hyaluronidase, an enzyme with the capacity to degrade hyaluronic acid in the extracellular matrix, which thereby enhances DNA transfer efficiency by 2- to 3-fold. This paper focuses on elucidating the mechanism of hyaluronidase’s impact on transfection efficiency. We demonstrate that hyaluronidase promotes a more uniform distribution of plasmid DNA (pDNA) within skeletal muscle. Additionally, our study investigates the effect of the timing of hyaluronidase pretreatment on EP efficiency by including time intervals of 0, 5, and 30 min between hyaluronidase treatment and the application of pulses. Serum levels of the pDNA-encoded transgene reveal a minimal influence of the hyaluronidase pretreatment time on the final serum protein levels following delivery in both mice and rabbit models. Leveraging bioimpedance measurements, we capture morphological changes in muscle induced by hyaluronidase treatment, which result in a varied pDNA distribution. Subsequently, these findings are employed to optimize EP electrical parameters following hyaluronidase treatment in animal models. This paper offers novel insights into the potential of hyaluronidase in enhancing the effectiveness of in vivo EP, as well as guides optimized electroporation strategies following hyaluronidase use.